Next-Gen Immunotherapies: Integrating Innate and Adaptive Immunity
We are pioneering a new generation of autologous T-cell-based therapies that uniquely combine attributes of macrophages and dendritic cells of the innate immune system with those of T cells (adaptive immune system) for treatment of both hematologic and solid tumor cancers. This integrated approach draws on recent advances in synthetic and T cell biology with the intent to increase the curative potential and safety profile of current therapies.